Neuland Laboratories News and Updates

Pharmaceuticals company Neuland Laboratories announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Total Income for Q2FY25 at Rs 315.2 crore (-25.1% YoY). EBITDA for Q2FY25 at Rs 65.7 crore (-53.2% YoY). EBITDA Margin for Q2FY25 at 20.8% (decreased by 1260 bps YoY). PAT for Q2FY25 at Rs 32.0 crore (-64.1% YoY)*. Net Debt stood at Rs -94.3 crore as at Q2FY25 end compared to Rs -39.2 crore as at Q2FY24 end and Rs -110.2 crore as at Q1FY25 end. H1FY25 Financial Highlights: Total Income for H1FY25 at Rs 759.6 crore (-3.3% YoY). EBITDA for H1FY25 at Rs 194.3 crore (-18.9% YoY). EBITDA Margin for H1FY25 at 25.6% (decreased by 490 bps YoY). PAT for H1FY25 at Rs 130.3 crore (-13.9% YoY)*. Net Debt stood at Rs -94.3 crore as at H1FY25 end compared to Rs -39.2 crore as at H1FY24 end. Sucheth Davuluri: “The numbers of this quarter are subpar relative to how the business has been performing over the last few quarteRs However, they are in line with our commentary right at the beginning of the year as to how we see FY25 panning out. The inherent uneven nature of our business means that annual progression is a better indicator of the company’s prospects than quarterly performance. We continue to make progress on our strategic plans and are enthusiastic about sustainable long-term growth driven by customer acquisitions, deepening capabilities, agile capacity expansion and optimization of processes.” Saharsh Davuluri: “The revenues this quarter were driven by a few key molecules on the commercial CMS and GDS specialty side. Completion of additional manufacturing facilities in this year coupled with anticipated commercial launch of molecules on the CMS side gives us the confidence of achieving high growth in FY26 and beyond. We believe that the environment remains favourable for us in the medium to long term as indicated by customer interest and addition of early-stage projects.” Result PDF

58.73% Gain from 52W Low

Neuland Laboratories News and Updates

Keep track of all breaking news on Neuland Laboratories from all sources in a single place.